News

In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...
Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.
As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...
Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...
This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...
Purported miracle medicines have always been with us. In the 1800s, traveling salesmen hawked cure-all elixirs. Nowadays, companies peddle myriad supplements on the internet, often with spurious ...
After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...
Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...
Today, Biogen and Eisai announced they would terminate the Phase 3 ENGAGE and EMERGE trials of aducanumab for early Alzheimer’s disease. A futility analysis run by an independent data-monitoring ...
Two Phase 3 trials testing elenbecestat in early AD are stopping. The trials were halted due to safety concerns. Elenbecestat was the last active BACE inhibitor trial for AD.
Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...